Wall Street Zen upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT – Free Report) from a strong sell rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.
A number of other equities research analysts have also issued reports on the stock. Chardan Capital restated a “neutral” rating and set a $1.50 price target on shares of Inhibikase Therapeutics in a report on Thursday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Inhibikase Therapeutics in a research note on Thursday, November 12th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.75.
View Our Latest Stock Report on Inhibikase Therapeutics
Inhibikase Therapeutics Trading Down 4.6%
Shares of IKT opened at $1.45 on Friday. The business’s 50-day moving average price is $1.87 and its 200 day moving average price is $1.93. The stock has a market capitalization of $203.39 million, a P/E ratio of -3.62 and a beta of 0.94. Inhibikase Therapeutics has a 1-year low of $1.40 and a 1-year high of $2.61.
Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. On average, research analysts predict that Inhibikase Therapeutics will post -0.41 earnings per share for the current year.
Hedge Funds Weigh In On Inhibikase Therapeutics
A number of large investors have recently made changes to their positions in IKT. Kalehua Capital Management LLC raised its stake in shares of Inhibikase Therapeutics by 118.4% during the 1st quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock worth $6,421,000 after purchasing an additional 2,071,890 shares in the last quarter. SummitTX Capital L.P. acquired a new stake in shares of Inhibikase Therapeutics during the 1st quarter valued at about $2,561,000. Ally Bridge Group NY LLC acquired a new stake in shares of Inhibikase Therapeutics during the 1st quarter valued at about $2,226,000. Soleus Capital Management L.P. grew its stake in shares of Inhibikase Therapeutics by 3.2% in the 3rd quarter. Soleus Capital Management L.P. now owns 11,225,000 shares of the company’s stock valued at $23,067,000 after buying an additional 350,000 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Inhibikase Therapeutics in the 2nd quarter valued at approximately $615,000. Institutional investors and hedge funds own 3.81% of the company’s stock.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.
Further Reading
- Five stocks we like better than Inhibikase Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
